HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes.

AbstractINTRODUCTION:
Conventional therapy for venous thromboembolism or acute coronary syndrome involves the administration of glycoanticoagulants (heparins) or oligosaccharides (fondaparinux). We evaluated the effects of such drugs on angiogenesis and vasculogenesis-like models.
MATERIALS AND METHODS:
Human umbilical vein endothelial cells or human endothelial progenitor cells were treated with bemiparin, fondaparinux or unfractionated heparin, at concentrations reflecting the doses used in clinical practice. After 24h, cell viability, proliferation, tubule formation and angiogenic molecular mechanisms, such as activation of the serine/threonine kinase AKT, were assessed. In vivo angiogenesis was studied using a Matrigel sponge assay in mice.
RESULTS:
Bemiparin gave a significant decrease of in vitro angiogenesis as shown by the reduction of endothelial cell tubule network, while both fondaparinux and unfractionated heparin did not show any significant effect. In assays of Matrigel sponge invasion in mice, unfractionated heparin was able to stimulate angiogenesis and, conversely, bemiparin inhibited angiogenesis. Furthermore, both bemiparin and fondaparinux caused a significant reduction in an in vitro vasculogenesis-like model, as demonstrated by the decrease of tubule network after co-seeding of endothelial progenitor cells and human umbilical vein endothelial cells. In addition, unfractionated heparin but not bemiparin was able to increase AKT phosphorylation.
CONCLUSIONS:
In in vitro experiments, bemiparin was the only drug to show an anti-angiogenic and vasculogenic-like effect, unfractionated heparin showed only a trend to increase in angiogenesis assay and fondaparinux affected only the vasculogenesis-like model. Notably, the in vivo experiments corroborated these data. Such results are important for the choice of a patient-tailored therapy.
AuthorsEleonora Da Pozzo, Maria Chiara Barsotti, Sara Bendinelli, Alma Martelli, Vincenzo Calderone, Alberto Balbarini, Claudia Martini, Rossella Di Stefano
JournalThrombosis research (Thromb Res) Vol. 130 Issue 3 Pg. e113-22 (Sep 2012) ISSN: 1879-2472 [Electronic] United States
PMID22497885 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Polysaccharides
  • Fondaparinux
  • bemiparin
Topics
  • Animals
  • Anticoagulants (pharmacology)
  • Cell Differentiation (drug effects)
  • Cells, Cultured
  • Endothelial Cells (cytology, drug effects, physiology)
  • Fondaparinux
  • Heparin, Low-Molecular-Weight (pharmacology)
  • Humans
  • Mice
  • Neovascularization, Physiologic (drug effects, physiology)
  • Polysaccharides (pharmacology)
  • Stem Cells (cytology, drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: